Posted by Michael Wonder on 08 Oct 2025
Werewolf Therapeutics receives fast track designation from the US FDA for WTX-124, an investigational therapy for the treatment of cancer
8 October 2025 - Werewolf Therapeutics today announced that the Company has received fast track designation for the use of WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma after standard of care immunotherapy.
WTX-124 is a conditionally activated interleukin 2 (IL-2) INDUKINE therapy.
